Company intelligence / Profile preview

Aviron

Mountain View, California, United Statessec.gov ↗

Ownership: Private
Development stage: Preclinical

Overview

Aviron developed innovative vaccines such as FluMist and advanced a pipeline of antivirals against hepatitis C. Their lead combination product AVIRUS® showed strong preclinical activity and favorable Phase I/II results in safety/tolerability. CONESCO®, a next-generation NS5A inhibitor, has demonstrated high efficacy in challenging patient populations with anticipated regulatory approval soon. The original vaccine business was acquired by MedImmune in 2002 for $1.5 billion after successful commercialization of FluMist.

Therapeutic areas: Infectious Diseases
Modalities: Vaccines (live virus, nasal mist)Small molecules/Direct acting antivirals
Industry: Biotech

Partnerships

MedImmuneARCH Venture PartnersAdams Street PartnersAbingworthSofinnova Ventures

Beyond the preview

Go deeper on Aviron.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Aviron.

Explore the full profile